Literature DB >> 30850560

Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series.

Martin Benesch1, Martin Mynarek2, Hendrik Witt3,4,5, Monika Warmuth-Metz6, Torsten Pietsch7, Brigitte Bison6, Stefan M Pfister3,4,5, Kristian W Pajtler3,4,5, Marcel Kool3,4, Ulrich Schüller2,8,9, Klaus Pietschmann10, Björn-Ole Juhnke2, Stephan Tippelt11, Gudrun Fleischhack11, Irene Schmid12, Christof M Kramm13, Peter Vorwerk14, Andreas Beilken15, Carl Friedrich Classen16, Pablo Hernáiz Driever17, Gabriele Kropshofer18, Thomas Imschweiler19, Andreas Lemmer20, Rolf-Dieter Kortmann10, Stefan Rutkowski2, Katja von Hoff21,17.   

Abstract

BACKGROUND: Data on frequency, clinical presentation, and outcome of primary metastatic intracranial ependymoma in children are scarce. PATIENTS AND METHODS: Prospective data on patients younger than 21 years with metastatic intracranial ependymoma at first diagnosis, registered from 2001 to 2014 in the HIT-2000 trial and the HIT-2000 Interim Registry, were analyzed.
RESULTS: Of 453 registered patients with intracranial ependymoma and central neuropathology review, initial staging included spinal magnetic resonance imaging in all patients and lumbar cerebrospinal fluid (CSF) analysis in 402 patients. Ten patients (2.2%) had metastatic disease, including three with microscopic CSF positivity only (M1 metastasis stage, 0.7% of patients with CSF staging). Location of the primary tumor was supratentorial in four patients (all supratentorial RELA-fused ependymoma [ST-EPN-RELA]) and within the posterior fossa in five patients (posterior fossa ependymoma type A [PF-EPN-A], n = 4; posterior fossa ependymoma not further classifiable, n = 1), and multifocal in one patient.All four patients with ST-EPN-RELA were alive in first or second complete remission (CR) 7.5-12.3 years after diagnosis. All four patients with macroscopic metastases of posterior fossa or multifocal ependymoma died. Three patients with initial M1 stage (ST-EPN-RELA, n = 1; PF-EPN-A, n = 2) received chemotherapy and local irradiation and were alive in second or third CR 3.0-9.7 years after diagnosis. Progression-free and overall survival of the entire cohort at 5 years was 13% (±6%), and 58% (±16%), respectively.
CONCLUSION: Primary metastatic disease is rare in children with intracranial ependymoma. Prognosis may depend on molecular subgroup and extent of dissemination, and relevance of CSF analysis for initial staging remains to be clarified. IMPLICATIONS FOR PRACTICE: Childhood ependymoma presenting with metastasis at first diagnosis is very rare with a frequency of 2.4% in this population-based, well-characterized cohort. Detection of microscopic metastases in the cerebrospinal fluid was extremely rare, and impact on prognosis and respective treatment decision on irradiation field remains unclear. Initial metastatic presentation occurs in both supratentorial RELA-fused ependymoma and posterior fossa ependymoma. Prognosis may differ according to extent of metastasis and biological subgroup, with poor prognosis in diffusely spread metastatic posterior fossa ependymoma even after combination therapy with both intensive chemotherapy and craniospinal irradiation, which may help to guide individual therapeutic decisions for future patients. © AlphaMed Press 2019.

Entities:  

Keywords:  Children; Intracranial ependymoma; Metastases; Molecular subgroups; Therapy

Mesh:

Year:  2019        PMID: 30850560      PMCID: PMC6738295          DOI: 10.1634/theoncologist.2018-0489

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  46 in total

1.  Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups.

Authors:  Sara Dyer; Emma Prebble; Val Davison; Paul Davies; Pramila Ramani; David Ellison; Richard Grundy
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  CSF cytology has limited value in the evaluation of patients with ependymoma who have MRI evidence of metastasis.

Authors:  Igor M Poltinnikov; Thomas E Merchant
Journal:  Pediatr Blood Cancer       Date:  2006-08       Impact factor: 3.167

3.  Role of radiotherapy in anaplastic ependymoma in children under age of 3 years: results of the prospective German brain tumor trials HIT-SKK 87 and 92.

Authors:  Beate Timmermann; Rolf-Dieter Kortmann; Joachim Kühl; Stefan Rutkowski; Karin Dieckmann; Christof Meisner; Michael Bamberg
Journal:  Radiother Oncol       Date:  2005-11-21       Impact factor: 6.280

4.  Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology.

Authors:  J Grill; M C Le Deley; D Gambarelli; M A Raquin; D Couanet; A Pierre-Kahn; J L Habrand; F Doz; D Frappaz; J C Gentet; C Edan; P Chastagner; C Kalifa
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

5.  Combined postoperative irradiation and chemotherapy for anaplastic ependymomas in childhood: results of the German prospective trials HIT 88/89 and HIT 91.

Authors:  B Timmermann; R D Kortmann; J Kühl; C Meisner; I Slavc; T Pietsch; M Bamberg
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-15       Impact factor: 7.038

6.  Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma.

Authors:  Frank Mendrzyk; Andrey Korshunov; Axel Benner; Grischa Toedt; Stefan Pfister; Bernhard Radlwimmer; Peter Lichter
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

7.  Radial glia cells are candidate stem cells of ependymoma.

Authors:  Michael D Taylor; Helen Poppleton; Christine Fuller; Xiaoping Su; Yongxing Liu; Patricia Jensen; Susan Magdaleno; James Dalton; Christopher Calabrese; Julian Board; Tobey Macdonald; Jim Rutka; Abhijit Guha; Amar Gajjar; Tom Curran; Richard J Gilbertson
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

8.  Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group.

Authors:  J Russell Geyer; Richard Sposto; Mark Jennings; James M Boyett; Richard A Axtell; David Breiger; Emmett Broxson; Bernadine Donahue; Jonathan L Finlay; Joel W Goldwein; Linda A Heier; Dennis Johnson; Claire Mazewski; Douglas C Miller; Roger Packer; Diane Puccetti; Jerilynn Radcliffe; May Lin Tao; Tania Shiminski-Maher
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

9.  Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study.

Authors:  Maura Massimino; Lorenza Gandola; Felice Giangaspero; Alessandro Sandri; Pinuccia Valagussa; Giorgio Perilongo; Maria Luisa Garrè; Umberto Ricardi; Marco Forni; Lorenzo Genitori; Giovanni Scarzello; Filippo Spreafico; Salvina Barra; Maurizio Mascarin; Bianca Pollo; Martina Gardiman; Armando Cama; Pierina Navarria; Maurizio Brisigotti; Paola Collini; Rita Balter; Paola Fidani; Maurizio Stefanelli; Roberta Burnelli; Paolo Potepan; Marta Podda; Guido Sotti; Enrico Madon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-04-01       Impact factor: 7.038

10.  Subdural enhancement on postoperative spinal MRI after resection of posterior cranial fossa tumours.

Authors:  M Warmuth-Metz; J Kühl; J Krauss; L Solymosi
Journal:  Neuroradiology       Date:  2004-02-26       Impact factor: 2.804

View more
  5 in total

1.  Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma.

Authors:  Soumen Khatua; Laurence J N Cooper; David I Sandberg; Leena Ketonen; Jason M Johnson; Michael E Rytting; Diane D Liu; Heather Meador; Prashant Trikha; Robin J Nakkula; Gregory K Behbehani; Dristhi Ragoonanan; Sumit Gupta; Aikaterini Kotrotsou; Tagwa Idris; Elizabeth J Shpall; Katy Rezvani; Rivka Colen; Wafik Zaky; Dean A Lee; Vidya Gopalakrishnan
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

2.  Evaluation of dose, volume, and outcome in children with localized, intracranial ependymoma treated with proton therapy within the prospective KiProReg Study.

Authors:  Sarah Peters; Julien Merta; Laura Schmidt; Danny Jazmati; Paul-Heinz Kramer; Cristoph Blase; Stephan Tippelt; Gudrun Fleischhack; Annika Stock; Brigitte Bison; Stefan Rutkowski; Torsten Pietsch; Rolf-Dieter Kortmann; Beate Timmermann
Journal:  Neuro Oncol       Date:  2022-07-01       Impact factor: 13.029

Review 3.  MR Imaging of Pediatric Brain Tumors.

Authors:  Alok Jaju; Kristen W Yeom; Maura E Ryan
Journal:  Diagnostics (Basel)       Date:  2022-04-12

Review 4.  Pediatric ependymoma: an overview of a complex disease.

Authors:  Stephanie Theresa Jünger; Beate Timmermann; Torsten Pietsch
Journal:  Childs Nerv Syst       Date:  2021-05-18       Impact factor: 1.475

Review 5.  Childhood Malignant Brain Tumors: Balancing the Bench and Bedside.

Authors:  Colin Thorbinson; John-Paul Kilday
Journal:  Cancers (Basel)       Date:  2021-12-03       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.